Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753545 · ClinicalTrials.gov registry record · Phase 2
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT00753545 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 265 participants.
The verdict
NCT00753545, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
Interventions
- DRUG matching placebo
- DRUG AZD2281
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2008-08-28 |
| Est. Completion | 2023-10-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00753545
The ClinicalTrials.gov registry entry for NCT00753545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which matching placebo is the first listed.
NCT00753545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00753545 about?
NCT00753545 is a clinical study titled "Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer". The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
What is the current status of trial NCT00753545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2008-08-28. Estimated completion is 2023-10-12.
What interventions are being tested in trial NCT00753545?
The interventions under investigation include: matching placebo (DRUG), AZD2281 (DRUG).
Who is sponsoring clinical trial NCT00753545?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.